| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012875830 |
| P356 | DOI | 10.1007/S00467-016-3563-6 |
| P932 | PMC publication ID | 5735842 |
| P698 | PubMed publication ID | 28013381 |
| P50 | author | Meredith A Atkinson | Q89522909 |
| Stephen P Juraschek | Q91329107 | ||
| Susan L Furth | Q92832050 | ||
| P2093 | author name string | Edgar R Miller | |
| Barbara Detrick | |||
| Michael S Bertenthal | |||
| P2860 | cites work | Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization | Q24310115 |
| New equations to estimate GFR in children with CKD | Q24642417 | ||
| Vitamin D and anemia: insights into an emerging association | Q28084642 | ||
| Anemia of inflammation: the hepcidin link | Q28236388 | ||
| Suppression of iron-regulatory hepcidin by vitamin D | Q28301486 | ||
| Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial | Q30317725 | ||
| Nonclassic actions of vitamin D | Q33375907 | ||
| Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias | Q33559201 | ||
| Hepcidin antagonists for potential treatments of disorders with hepcidin excess | Q33563777 | ||
| The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease | Q33825492 | ||
| Reduction of serum hepcidin by hemodialysis in pediatric and adult patients | Q33888363 | ||
| The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes | Q33993335 | ||
| Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. | Q33999246 | ||
| Cellular catabolism of the iron-regulatory peptide hormone hepcidin | Q34639451 | ||
| Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity | Q34739582 | ||
| Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort | Q35106901 | ||
| Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings | Q35154069 | ||
| Hepcidin and cytokines in anaemia | Q36069473 | ||
| Vitamin D supplementation in pre-dialysis chronic kidney disease: A systematic review | Q36187587 | ||
| Hepcidin in anemia and inflammation in chronic kidney disease. | Q36704221 | ||
| Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial | Q36944692 | ||
| Hepcidin--a potential novel biomarker for iron status in chronic kidney disease | Q37211057 | ||
| Serum IL-6 levels are associated with significant coronary stenosis in cardiovascularly asymptomatic inner-city black adults in the US. | Q37331764 | ||
| Vitamin D, race, and risk for anemia in children | Q37412806 | ||
| Vitamin D insufficiency: implications for the immune system | Q37697636 | ||
| Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. | Q37750540 | ||
| Current status of the measurement of blood hepcidin levels in chronic kidney disease. | Q37781229 | ||
| Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist | Q37852626 | ||
| Diagnostic potential of hepcidin testing in pediatrics. | Q39462117 | ||
| High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults | Q39611816 | ||
| Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. | Q39861926 | ||
| Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5. | Q44125749 | ||
| Diurnal rhythm rather than dietary iron mediates daily hepcidin variations | Q46246095 | ||
| Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. | Q46290245 | ||
| Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration | Q48239445 | ||
| A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. | Q50578930 | ||
| 25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. | Q51819966 | ||
| A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity | Q55879648 | ||
| Immunoassay for human serum hepcidin | Q56489921 | ||
| Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients | Q79572961 | ||
| Erythropoiesis-stimulating agents--time for a reevaluation | Q82418400 | ||
| Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis | Q82433204 | ||
| KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary | Q83385679 | ||
| Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients | Q84611960 | ||
| P433 | issue | 5 | |
| P921 | main subject | cholecalciferol | Q139347 |
| chronic renal insufficiency | Q736715 | ||
| P304 | page(s) | 859-868 | |
| P577 | publication date | 2016-12-24 | |
| P1433 | published in | Pediatric Nephrology | Q15749796 |
| P1476 | title | Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial | |
| P478 | volume | 32 |
Search more.